Shaanxi Meibang Pharmaceutical Group Co., Ltd. (SHA:605033)
China · Delayed Price · Currency is CNY 19.15
-0.44 (-2.25%)
Aug 17, 2026, 3:00 PM CST
SHA:605033 Ratios and Metrics
Market cap in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 14, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 2,589 | 2,715 | 1,626 | 2,427 | 2,359 | 3,611 | |
Market Cap Growth | -10.05% | 66.92% | -32.98% | 2.88% | -34.67% | - |
Enterprise Value | 2,371 | 2,222 | 1,176 | 2,126 | 2,060 | 3,339 |
Last Close Price | 19.15 | 19.97 | 11.88 | 17.45 | 16.44 | 25.46 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 14, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 40.79 | 55.79 | 44.13 | 42.16 | 16.26 | 28.72 |
PS Ratio | 2.64 | 2.98 | 1.84 | 3.47 | 2.60 | 4.29 |
PB Ratio | 2.17 | 2.35 | 1.45 | 2.18 | 2.17 | 3.74 |
P/TBV Ratio | 2.41 | 2.62 | 1.62 | 2.35 | 2.20 | 3.77 |
P/FCF Ratio | - | 60.69 | 13.38 | 18.51 | 137.78 | - |
P/OCF Ratio | 22.62 | 11.84 | 5.80 | 7.25 | 18.66 | - |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 14, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 2.42 | 2.44 | 1.33 | 3.04 | 2.27 | 3.96 |
EV/EBITDA Ratio | 22.32 | 30.18 | 28.95 | 33.34 | 13.73 | 24.63 |
EV/EBIT Ratio | 35.02 | 52.39 | 62.31 | 49.56 | 15.31 | 27.13 |
EV/FCF Ratio | - | 49.66 | 9.67 | 16.22 | 120.32 | - |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 14, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.13 | 0.13 | 0.07 | 0.00 | - | 0.03 |
Debt / EBITDA Ratio | 1.49 | 2.05 | 1.80 | 0.02 | - | 0.20 |
Debt / FCF Ratio | - | 3.37 | 0.60 | 0.01 | - | - |
Net Debt / Equity Ratio | -0.18 | -0.53 | -0.52 | -0.43 | -0.37 | -0.39 |
Net Debt / EBITDA Ratio | -2.05 | -8.34 | -14.36 | -7.53 | -2.66 | -2.77 |
Net Debt / FCF Ratio | 6.66 | -13.71 | -4.80 | -3.66 | -23.34 | 1.74 |
Asset Turnover | 0.55 | 0.46 | 0.50 | 0.43 | 0.60 | 0.75 |
Inventory Turnover | 4.16 | 2.49 | 2.12 | 1.18 | 1.04 | 1.27 |
Quick Ratio | 2.01 | 1.18 | 1.21 | 1.39 | 1.69 | 1.14 |
Current Ratio | 2.79 | 1.64 | 1.78 | 2.33 | 3.21 | 2.73 |
Return on Equity (ROE) | 5.44% | 4.27% | 3.29% | 5.23% | 14.13% | 17.76% |
Return on Assets (ROA) | 2.35% | 1.35% | 0.66% | 1.65% | 5.56% | 6.84% |
Return on Invested Capital (ROIC) | 6.52% | 7.29% | 3.13% | 5.99% | 20.05% | 26.49% |
Return on Capital Employed (ROCE) | 4.50% | 3.10% | 1.50% | 3.50% | 11.30% | 12.00% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 14, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | 2.46% | 1.79% | 2.27% | 2.37% | 6.15% | 3.48% |
FCF Yield | -1.26% | 1.65% | 7.48% | 5.40% | 0.73% | -5.96% |
Dividend Yield | 0.77% | 0.75% | 1.22% | 0.86% | 1.34% | 0.75% |
Payout Ratio | 38.64% | 49.51% | 76.62% | 51.82% | 18.38% | 2.62% |
Buyback Yield / Dilution | 0.17% | 0.98% | -1.99% | 1.29% | -22.93% | -9.27% |
Total Shareholder Return | 0.94% | 1.73% | -0.77% | 2.15% | -21.59% | -8.53% |